Up to now, there had been no randomized controlled trial assessing oral anticoagulation alone vs. oral anticoagulation plus antiplatelet therapy in patients with atrial fibrillation 1 year after stenting in a setting of stable coronary disease. Such was the vacuum that this work, presented at TCT 2018 and published simultaneously in Circulation, attempted to fill. This trial...
TCT 2018 | IMPERIAL: First Study Comparing Drug-Eluting Stents in Patients with Femoropopliteal Disease
The IMPERIAL trial compared the safety and efficacy of a nitinol self-expanding polymer-free placlitaxel-eluting stent (Zilver PTX, Cook Medical, already approved by the US Food and Drug Administration [FDA]) and a nitinol self-expanding polymer-coating placlitaxel-eluting stent (Eluvia, Boston Scientific). This was a single-blind randomized trial in patients with symptomatic intermittent claudication (Rutherford categories 2, 3, or...
Direct Stenting vs. Conventional Angioplasty and Their Interaction with Thrombus Aspiration
The rates of direct stenting are higher among patients randomized to thrombus aspiration. The rates of clinical events and myocardial reperfusion did not differ significantly between a direct stenting strategy vs. predilation and stenting, and no interaction was observed as regards thrombus aspiration. Several preliminary studies have emerged from the hypothesis that a direct stenting...
OCT Provides Hints About the Physiopathology Behind Very Late Stent Thrombosis
Neoatherosclerosis was frequently observed in patients who experienced very late stent thrombosis, particularly those with drug-eluting stents. In-stent plaque rupture was the most common cause of thrombosis and it usually occurred in cases in which the original procedure had been carried out while the patient was undergoing an acute myocardial infarction. Macrophage infiltration can be...
SOLACI-SOCIME 2018 | Bio Active Stents
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Pasi Karjalainen, entitled “Bio Active Stents”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI-SOCIME 2018 | How to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Christopher White, entitled “ How to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.f
Post Carotid Stenting Cerebral Hyperperfusion: a Preventable Complication
This syndrome, which can be reverted, is also one of the causes of preventable stroke, at least in the context of carotid endarterectomy. At present, there is little information on the incidence of this condition in the context of carotid stenting, which is the purpose of this study, in addition to providing tips to prevent it....
EuroPCR 2018 | Consistent CTO Study: Rechanneling with Current Techniques and SYNERGY Stents
This observational study included 231 patients from 6 sites who presented chronic total occlusions and underwent rechanneling procedures using currently available techniques, which were successful in 90% of all cases (210 patients). All patients who underwent successful rechanneling received a SYNERGY stent and most of them underwent intravascular ultrasound (90.5%). There was only 1 patient lost to clinical follow-up...
Antithrombotics after Venous Stenting: Rather Different from Coronary Artery Stenting
Should the Antithrombotic/antiplatelet therapy following 10.0 by 60 mm stent implantation to the subclavian vein of a chronic kidney patient be the same as one following a 3.0 by 18 mm stent implantation to the second segment of the left anterior descending artery of this same patient? The daily practice of many interventional cardiologists performing...
ACC 2018 | COMBO: New Stent with Thin Struts and Pro-Healing Membrane
The new COMBO stent, comprised of thin struts plus a bioengineered layer of endothelial progenitor cells, is safe and effective at 1 year, according to this registry (the largest study on this device to date). This new stent could provide a better option for patients at high risk for bleeding who may not be able to...